Search Results - marc+greenberg

6 Results

Sort By:

Identification of DNA Polymerase Theta Inactivation Mechanism

Unmet NeedLoss of DNA repair is an early and frequent event in the growth of tumors, occurring in 40 to 50% of breast, lung and ovarian cancer patients. The inability to repair damaged DNA provides a selective growth advantage to tumor cells as this results in genetic instability and enhanced mutation rates, which can drive tumor growth. These DNA...

Published: 9/26/2024 | Inventor(s): Marc Greenberg, Daniel Laverty

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Gene Therapies, Technology Classifications > Therapeutic Modalities > Cell Therapies

Novel selective, covalent inhibitors of DNA polymerase beta, and synthetic lethality in BRCA-deficient cancer

Unmet Need / Invention Novelty: Poly(ADP-ribose) polymerase 1 (PARP1) inhibitors are known synthetic lethal partners for breast cancer gene (BRCA) 1- and 2-deficient cancers. However, not all BRCA-deficient cancers are susceptible to PARP1 inhibitors and others develop resistance. Furthermore, DNA polymerase beta is overexpressed in many cancers, decreasing...

Published: 9/27/2024 | Inventor(s): Marc Greenberg, Shelby Yuhas

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology > Breast Cancer, Technology Classifications > Therapeutic Modalities > Targets

Solid-phase Synthesis of Oligonucleotides Containing N6-(2-Deoxy-alpha,beta-D-erythropentofuranosyl)-2,6-diamino-4-hydroxy-5-formamidopyrimidine (Fapy•dG)

Unmet Need: Study of the common DNA damage oxidative lesion Fapy∙dG has been extremely limited due to the lack of tools available to synthesize oligonucleotides containing this lesion. Technical Details: Johns Hopkins researchers have developed a solid-phase synthetic method to prepare oligonucleotides containing N6-(2-Deoxy-α,β-D-erythropentofuranosyl)-2,6-diamino-4-hydroxy-5-formamidopyrimidine...

Published: 9/27/2024 | Inventor(s): Marc Greenberg, Haozhe Yang

Keywords(s):

Category(s): Technology Classifications > Research Tools > Nucleic Acids

Irreversible Inhibitors of DNA Polymerase (Beta)

Unmet Need: Targeted cancer therapies against DNA repair enzymes have successfully been implemented in cancer treatments but now suffer from the development of drug resistance. There is a need for additional DNA repair enzyme targets to overcome current resistance issues. Technical Details: Johns Hopkins researchers have identified an inhibitor of DNA...

Published: 9/26/2024 | Inventor(s): Mohammad Hedayati, Dumitru Arian, Theodore DeWeese, Marc Greenberg

Keywords(s): Antagonists/Inhibitors, Cancers, Disease Indication, Novel, Predicted Novelty, Prostate Cancer, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Men's Health, Clinical and Disease Specializations > Oncology > Prostate Cancer, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities

DNA Polymerase Beta Inhibitors

INVENTION NOVELTYJohns Hopkins researchers have developed multiple unique inhibitors to DNA polymerase beta, a potential anti-cancer therapeutic target. VALUE PROPOSITIONThe DNA damaging agent temozolomide (TMZ) is used to treat melanoma and glioblastoma. TMZ damages cancer cell DNA by introducing single stranded breaks (SSBs). However TMZ’s efficacy...

Published: 9/26/2024 | Inventor(s): Marc Greenberg, Rakesh Paul

Keywords(s): Antagonists/Inhibitors, Cancers, Chemotherapy/Targeted Therapy, Combination, Disease Indication, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities

Nucleotides that Produce DNA Interstrand Cross-links

C04741: Method of clearing a DNA lesion to make DNA-related therapy more effectiveValue Proposition: • This efficient process should provide the great force to design novel DNA cross-linking agents. • From research point of view, this technology will greatly facilitate the study of the biological effects of this important family of DNA...

Published: 9/26/2024 | Inventor(s): Marc Greenberg

Keywords(s): Biomarker, Cancers, Cloning Reagents, Discovery/Research Tools, Disease Indication, Nucleotide, Pharmakodynamic Biomarker, Research Reagent, Therapeutic Matter, Therapeutics, Translational Research Biomarker

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Research Tools > Nucleic Acids, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Technology Classifications > Research Tools, Technology Classifications > Therapeutic Modalities